Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two companies will showcase the solution at the annual Society of Breast Imaging Symposium from April 11-14, 2024 in Montreal, Canada. Contrast-enhanced mammography is a sensitive and relatively low-cost breast imaging modality that can be used to support breast cancer diagnosis and help to guide treatment.1 The offering brings together Hologic?s leading mammography technologies and Bayer?s leading contrast-enhanced mammography contrast delivery system, the MEDRAD® Stellant FLEX Computed Tomography (CT) Injection System.

The MEDRAD Stellant FLEX CT Injection System with Certegra® Workstation is the first and only CT injection system 510(k) cleared with an additional contrast-enhanced mammography application. By working together, Hologic and Bayer are streamlining the purchasing process for radiologists and imaging facilities, providing a seamless set-up and ongoing, supportive educational resources. About Contrast-Enhanced Mammography: Contrast-enhanced mammography is a breast imaging modality and the value of contrast-enhanced mammography as an adjunct to mammography is affirmed by an increasing number of independent scientific publications.

Contrast-enhanced mammography can be performed as part of an everyday clinical practice and used in various clinical settings, such as inconclusive findings in previous imaging procedures.